MicroIslet, Inc.

MicroIslet is specialised in islet transplantation therapy by use of a suspension of microencapsulated porcine islet cells

MicoIslet Inc (Amex: MII) is a development-stage biotechnology company that develops encapsulated islet cells for the transplantation into patients with insulin-dependent diabetes. MicroIslet has licensed its technology from Duke University Medical Center. The CEO John Steel owns 24% of the company.

Michael J. Andrews, CEO
Amaresh Basu, Ph.D., VP, Research and Development
Kevin A. Hainley, Interim CFO
Jonathan R. T. Lakey, Ph.D., President and CSO

Ronald Katz, Chairman
Robert W. Anderson, M.D.
Michael J. Andrews
Steven T. Frankel
Keith B. Hoffman, Ph.D.
Jonathan R. T. Lakey, Ph.D.
Barry Ritholtz

Bassam Damaj, Ph.D.
Athanassios Sambanis, Ph.D.
Nora Sarvetnick, Ph.D.

6370 Nancy Ridge Drive, Suite 112
San Diego, CA 92121
USA
Phone: +1-858-657-0287
Fax: +1-858-657-0288

MicroIslet-P™,the company’s first product, is a suspension of microencapsulated porcine islets for injection into the abdominal cavity. The microencapsulation is made from a highly biocompatible biopolymer (alginate) that protects the islet cells from the body’s immune system.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.